BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zyleris PharmaTech Release: High-Throughput Screening of Compound Library for Topical and Transdermal Delivery


4/26/2011 10:15:04 AM

Chicago, IL, U.S.A, April 26, 2011 – Zyleris PharmaTech (www.Zyleris.com) has announced the launch of a new drug development service: high-throughput screening of compound library to identify drug candidates for topical and transdermal delivery.

The screening service utilizes Zyleris’ Franz Cell-based high-throughput technology. Each screening system consists of a compact 108-cell screening station with flexibility for both absorption and penetration studies. The system is fully validated against industry-standard Franz Cell technology. It can be used with any human or animal tissue including skin, buccal, lung, ocular, nail (with adapter) or synthetic membrane.

For many local and system indications, topical and transdermal delivery is a valuable and often preferred option in the drug development process. However, current Franz Cell technology is ill-equipped for screening of compound library. The market is ripe for a high speed and yet cost efficient solution. Our system fills this gap. It will allow researchers to rapidly screen compound library and make informed, go/no-go decision with respect to the delivery route.

Zyleris’ objective is to continue developing innovative solutions, technologies, and services for topical and transdermal drug research and development.

About Zyleris PharmaTech

Founded in 2009 and headquartered in Chicago, IL, U.S.A, Zyleris PharmaTech is a contract research service company delivering best-in-class high-throughput experimentation technologies and services for accelerating topical and transdermal drug R&D process.

For more information about the company, please visit us at www.zyleris.com.

Contact Information

Jerry Zhang

Phone: 847-604-8474

Email: jerryzhang@zyleris.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES